ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1477

Circulating MicroRNAs in Hand Osteoarthritis

Aneta Pekacova1, Jiri Baloun1, Olga Sleglova1, Jiri Vencovsky1, Karel Pavelka2, Ladislav Senolt2 and Olga Ruzickova1, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Meeting: ACR Convergence 2021

Keywords: Biomarkers, Micro-RNA, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: microRNAs (miRNAs) are small non-coding RNAs that can ignite the degradation of mRNAs or inhibit the protein translation and are therefore essential for several physiological and pathological functions. It is now clear that several miRNAs (e.g. miR-9, miR-140) regulating genes related to OA progression have a significantly different levels of expression in various tissues 1,2. Under certain circumstances, miRNAs can be released into the body fluids and easily be detected in the blood samples.

The aim of this study was to evaluate circulating miRNAs in patients with hand osteoarthritis (HOA) and healthy individuals. Simultaneously, we studied specific miRNAs in order to differentiate between erosive and non-erosive subsets of the disease.

Methods: Eight patients with HOA (erosive: n=4, 3 females, mean age=63.7±7 yrs; non-erosive: n=4, 3 females, mean age= 62.4±6 yrs) and 4 healthy controls (3 females, mean age=63.5±7 yrs) were included in this study. Firstly, Advance TaqMan low-density assay (TLDA) was performed for the purpose of miRNA high-throughput screening. Differently expressed miRNAs were further verified by real-time qPCR on the validation cohort in 31 patients with hand OA (19 females, mean age=66.2±7 yrs, erosive: n=9, non-erosive: n=10, healthy controls: n=12).

Results: We identified 346 circulating miRNAs in plasma of HOA patients and healthy controls. Out of these, 40 circulating miRNAs were differently expressed in patients with HOA compared to healthy controls. We validated altered expression of 10 miRNAs in patients with HOA compared to healthy controls, e.g. miR-191-5p (3.4 fold), miR-151a-3p (3.4 fold) or miR-222-3p (2.4 fold). None of the miRNA could distinct erosive from a non-erosive subset of the disease.

Conclusion: Extensive profiling of circulating miRNAs revealed several miRNAs that can be associated with HOA and can help to better understand OA pathogenesis.

References:

1. Zhang H, Song B, Pan Z. Downregulation of microRNA-9 increases Matrix metalloproteinase-13 expression levels and facilitates osteoarthritis onset. Mol Med Rep. 2018;17(3):3708-3714. doi:10.3892/mmr.2017.8340

2. Chao Y, Zhang L, Zhang X, Ma C, Chen Z. Expression of miR-140 and miR-199 in synovia and its correlation with the progression of knee osteoarthritis. Med Sci Monit. 2020;26:1-6. doi:10.12659/MSM.918174

Acknowledgement: Supported by AZV NV18-01-00542, MHCR No. 023728, BBMRI-CZ LM2018125


Disclosures: A. Pekacova, None; J. Baloun, None; O. Sleglova, None; J. Vencovsky, AbbVie, 1, 6, Boehringer Ingelheim, 2, Eli Lilly, 1, 6, Gilead, 1, Octapharma, 1, Biogen, 6, MSD, 6, Pfizer, 6, Roche, 6, Sanofi, 6, UCB, 6, Novartis, 6, Werfen, 6; K. Pavelka, Abbvie, 6, UCB, 6, MSD, 6, Roche, 6, Pfizer, 6, Eli Lilly, 6, Egis, 6, Biogen, 6, Pfizer, 6; L. Senolt, None; O. Ruzickova, None.

To cite this abstract in AMA style:

Pekacova A, Baloun J, Sleglova O, Vencovsky J, Pavelka K, Senolt L, Ruzickova O. Circulating MicroRNAs in Hand Osteoarthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/circulating-micrornas-in-hand-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-micrornas-in-hand-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology